Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31571419 | 0.98 | SIGMAR1 (0.36) | SIGMAR1RAPGEF4ALDH1A1NPSR1MAPK1 | |
| SCHEMBL4611466 | 0.81 | SIGMAR1 (0.49) | SIGMAR1ALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL12190764 | 0.80 | APP (0.37) | SIGMAR1ALDH1A1NPSR1MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL28881296 | 0.79 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1NPSR1KDM4EMEN1 | |
| SCHEMBL18987023 | 0.79 | SIGMAR1 (0.39) | SIGMAR1RAPGEF4ALDH1A1NPSR1MAPK1 | |
| SCHEMBL24446513 | 0.79 | SIGMAR1 (0.40) | SIGMAR1RAPGEF4ALDH1A1NPSR1MAPK1 | |
| SCHEMBL30542166 | 0.79 | SIGMAR1 (0.40) | SIGMAR1RAPGEF4ALDH1A1NPSR1MAPK1 | |
| SCHEMBL29661763 | 0.78 | ALDH1A1 (0.41) | ALDH1A1NPSR1MAPK1MEN1KMT2A | |
| SCHEMBL19735030 | 0.78 | ALDH1A1 (0.41) | ALDH1A1NPSR1MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL838238 | 0.77 | SIGMAR1 (0.38) | SIGMAR1RAPGEF4ALDH1A1NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118908957-A | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114222737-B | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024028363-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2013120852-A1 | INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2013-08-22 | — | — | WO | disclosed |
| US-8507483-B2 | 1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation | SANOFI (FR) | 2013-08-13 | — | — | US | disclosed |
| US-8366963-B2 | Compound having hydrocoumarin skeleton, liquid crystal compostition, and liquid crystal display device | JNC CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
| US-7951305-B2 | Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | HCN2, PIEZO1, TRPV4 | SIGMAR1 2797/4885RAPGEF4 3624/4885ALDH1A1 3098/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SIGMAR1 3429/4885RAPGEF4 2258/4885ALDH1A1 4078/4885 |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, HCN2, HCN1 | SIGMAR1 1634/4885RAPGEF4 3786/4885ALDH1A1 3754/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | SIGMAR1 3429/4885RAPGEF4 2258/4885ALDH1A1 4078/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | SIGMAR1 4495/4885RAPGEF4 1524/4885ALDH1A1 1674/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SIGMAR1 3429/4885RAPGEF4 2258/4885ALDH1A1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.